NeXT Dx
- GTR Test IDHelpEach Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. When a laboratory updates a registered test, a new version number is assigned.: GTR000576389.11
- Last updated: 2024-07-01
- Test version history
- 576389.11, last updated: 2024-07-01
- 576389.10, last updated: 2024-06-27
- 576389.9, last updated: 2023-03-15
- 576389.8, last updated: 2022-03-18
- 576389.7, last updated: 2021-03-03
- 576389.6, last updated: 2020-08-25
- 576389.5, last updated: 2020-06-17
- 576389.4, last updated: 2020-05-19
- 576389.3, last updated: 2020-05-18
- 576389.2, last updated: 2020-05-14
- 576389.1, last updated: 2020-05-13
Clinical testHelpIn the U.S., clinical tests must be performed under CLIA certification. When a lab uses the same methods for a test in both clinical and research settings, the test appears as two separate GTR records. for Solid tumor
Offered by Personalis, Inc.
Overview
Test name
HelpThe name the laboratory assigns the test. Used as the default title of the page specific to the test.NeXT Dx
This is a clinical test intended for HelpPurposes or indications for the test. Lab-provided.: Prognostic, Therapeutic management
Click Indication tab for more information.
Contact clientservices@personalis.com
Order URL HelpLink to the laboratory webpage with information about how to order this test. Please note that clicking on this link will open a new tab in your internet browser.: https://www.nextdx.com/
Specimen source
Methodology
HelpThe assay's major method category (biochemical, cytogenetic or molecular genetics); method category (i.e. enzyme assay, chromosome breakage studies, targeted mutation analysis); methodology (i.e. the name of the method used) and instruments used when performing this test.- Molecular Genetics
- IMicrosatellite instability testing (MSI)
- Next-Generation (NGS)/Massively parallel sequencing (MPS)
- Illumina NovaSeq 6000
- NeXT Dx
- RRNA analysis
- Next-Generation (NGS)/Massively parallel sequencing (MPS)
- Illumina NovaSeq 6000
- NeXT Dx
- CSequence analysis of the entire coding region
- Next-Generation (NGS)/Massively parallel sequencing (MPS)
- Illumina NovaSeq 6000
- NeXT Dx
Guidance for management
- PMIDs 27993330, 30227640, 28481359, 28481359, 27782854, 26028255, 28835386, 29337640, 29658845, 25409260
Clinical validity
HelpHow consistently and accurately the test detects or predicts the intermediate or final outcomes of interest. Lab-provided.The Personalis NeXT Dx Test, based on the NeXT platform, should be considered when personalized therapeutic guidance is sought for patients with cancer. The NeXT Dx test is indicated for use on solid tumors where its required to send FFPE tumor tissue along with matched normal (blood or saliva), where samples are reviewed and selected by a pathologist as the most representative block for the patient’s diagnosis. The intended use of the NeXT Dx test is in-line with the rationale for molecular testing of cancers described in “Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists” (PMID 27993330). Specifically, the NeXT Dx test should be used in situations where a more complete knowledge of the molecular alteration status of a cancer may assist in making clinical diagnosis and treatment decisions, determining prognosis, and determining patient eligibility for clinical trials.
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. - PubMed ID: 27993330
Test services
HelpLaboratory's order or catalog code for the test (used in the order requisition form).- Result interpretation
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.